ClinicalTrials.gg
Not yet recruitingNCT05793567Updated Aug 31, 2026

A Study of Microcirculatory Function in Type 2 Myocardial Infarction (T2MI)

An observational study in Myocardial Infarction and Coronary Microvascular Disease, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-31.

Sponsored by Mayo Clinic · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
52
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Myocardial Infarction by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Myocardial Infarction · Mayo Clinic.

Started
2027
the only one that year
Observational
8 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Myocardial Infarction by Mayo Clinic, this one is the only one that started in 2027, is one of 8 observational ones, and was the 19th registered.

Myocardial Infarction

2,273 studies on the registry are indexed under Myocardial Infarction; 373 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

5 of the 19 studies in Myocardial Infarction by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 256 Myocardial Infarction studies recruiting now, 173 (68%) set no upper age limit and 25 (10%) stop at 75 or younger; 17 take children under 18; 27 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Myocardial Infarction by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this research is to find out if patients with Type 2 Myocardial Infarction (T2MI) without significant epicardial coronary artery disease (CAD) have a greater chance of having coronary microvascular disease (CMD).

03

Conditions studied

  • Myocardial Infarction
  • Coronary Microvascular Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Subjects receiving care at Mayo Clinic in Rochester, MN identified with T2MI and controls with atypical chest pain with indication for CMD testing will be enrolled in this study. Both groups will have no epicardial coronary stenosis >50% or obstructive disease.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ability to give
  • Structurally normal heart (normal LV and RV function, no more than mild valvular heart disease)
  • For controls: atypical chest pain with indication for CMD testing
  • For T2MI: meet criteria for T2MI according to the 4th Universal definition of MI (rise/fall of troponin with at least 1 value >99th centile+ evidence of symptoms or signs of myocardial ischemia)

Exclusion criteria

Exclusion Criteria:

  • Acute coronary event (evidence of plaque rupture, fissure or dissection on coronary angiogram)
  • Known to have angiographically significant CAD/pressure wire positive for epicardial CAD
  • Inability to receive heparin products
  • Allergy/ to acetylcholine/adenosine/nitroglycerine products
  • Prior coronary artery bypass grafting
  • Pregnancy (if sexually active woman of reproductive age, need negative pregnancy test prior to proceeding with coronary angiography - this is standard of care in cath lab)
  • Asthma with prior ICU admission due to bronchospasm/need for invasive ventilation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
52 participants (estimated)
Patient registry
No

Groups and cohorts

  • T2MI Patients

    Patients with T2MI and no epicardial coronary stenosis \>50% will be prospectively enrolled and undergo a routine standard of care coronary angiogram with coronary reactivity testing (CRT).

    Diagnostic Test: Coronary angiogram with coronary reactivity testing (CRT)

  • Controls

    Patients with atypical chest pain and no obstructive disease on coronary angiogram who have been referred for investigation of suspected CMD and have a clinical indication for CMD testing will be retrospectively enrolled and data collected from a previous routine standard of care coronary angiogram with coronary reactivity testing (CRT) will be utilized.

Interventions

  • Diagnostic testCoronary angiogram with coronary reactivity testing (CRT)

    CRT is an angiography procedure (using X-ray) to examine the small blood vessels in the heart and how they respond to three drugs (adenosine, acetylcholine and nitroglycerin) as per clinical protocol.

06

What researchers measure

Primary outcomes

  1. Coronary Flow Reserve (CFR)

    The CFR will be calculated as a ratio of coronary flow at peak hyperemia /coronary flow at rest.

    Time frame: Baseline

Secondary outcomes

  1. Backward Compression Wave (BCW)

    The BCW is a measure of increased microvascular resistance during systole.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jan 2028, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2023
First posted
Mar 31, 2023
StartEst.
Jan 2027
Primary completionEst.
Jan 2028
CompletionEst.
Jan 2028
Last update
Aug 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05793567
Lead sponsor
Mayo Clinic
Responsible party
Claire E. Raphael (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Mar 31, 2023
Start date
Jan 2027 (estimated)
Primary completion
Jan 2028 (estimated)
Completion
Jan 2028 (estimated)
Last update
Aug 31, 2026

Study contacts

Ischemic Heart Disease Research Team
Contact
507-255-1724
Claire Raphael, MBBS, PhD
Contact
Raphael.Claire@mayo.edu
507-255-2445
Claire Raphael, MBBS, PhD.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion